For Immediate Release
Prodesse announces licensing agreement with Roche
WAUKESHA, WI (June 30, 2006) – Prodesse, Inc. announced today that effective July 1, 2006 the company has entered into an IVD Patents License Agreement with Roche. Prodesse is now granted the right to manufacture real time products which laboratories can use to develop and validate assays for the detection of certain diagnostic targets with the additional authority to convey rights to the service provider. Commenting on the agreement, Prodesse CEO Tom Shannon remarked, “We are quite pleased that Prodesse is now able to include Roche enzymes in its products as well as convey end-user rights under their patents to its customers with sale of Prodesse products for influenza a virus, InFluenza B virus, RSV and human metapneumovirus.”
About Prodesse
Prodesse is a biotechnology company focused on developing molecular diagnostic reagents for a variety of infectious disease applications. The company’s products are designed based on a combination of Prodesse’s patented technologies and other licensed technologies. Prodesse sells research use only kits worldwide, CE Marked in vitro diagnostic kits outside the US , FDA 510(k) cleared products worldwide and analyte specific reagents in the US . Analyte specific reagents can be used by CLIA certified laboratories to develop assays for detecting infectious organisms. The company’s products can be used on multiple nucleic acid extraction and PCR detection platforms. Prodesse also operates a CLIA certified laboratory for testing services in the Midwest area. For more information about Prodesse and its products, call 888-589-6974 or go to www.prodesse.com.
Press Contact:
Andy Shrago, Chief Marketing Officer
Prodesse, Inc.
Phone: (262) 446-0700
Email: ashrago@prodesse.com